• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·PLSH
Share

Panacea Life Sciences Holdings, Inc. Stocks

$ 0.08Last Updated 23.10.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

$ 1.78M

$ 0.08
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Panacea Life Sciences Holdings, Inc. operates as an integrated research and production firm, specializing in cannabinoid and nutraceutical products across the entire supply chain, from sourcing to final sale. Its core mission is to develop and deliver natural, pharmaceutical-grade alternatives for both human and pet consumption. The company's diverse product range encompasses items such as softgels, edible gummies, liquid tinctures, sublingual tablets, and a variety of cosmetic and topical applications. In addition to these offerings, the company is involved in the personal protective equipment (PPE) market, importing and distributing hand sanitizers and masks. Panacea Life Sciences also provides white-label and contract manufacturing services to other cannabinoid companies, sells raw materials, and manages tolling arrangements. Established in 2008, the company is headquartered in Greenwood Village, Colorado.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is 'cheaper' than its peers. In particular, the stock is undervalued on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

25.10.2026 22:01

Solidigm Won't Go Public; New OpenAI Valuation: Key Points on the IPO by October 25

24.10.2026 16:01

Highlights in Small-Cap Stocks: The Merck Deal, the Success of a Hair Loss Pill, and Braze's "Wow Factor"

24.10.2026 13:01

AI investors are already on the brink, a “French kiss” for the euro, and hackers at the gates

24.10.2026 05:04

Hedge funds ramp up bets against euro to highest level since 2020

24.10.2026 04:46

France avoids Moody’s downgrade after a week of turmoil

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026